Thomas Hohman, Scientific Advisor
Thomas Hohman, PhD in Cell Biology from University of California, Los Angeles, brings 30 years of experience in ophthalmology drug and clinical development in senior executive roles at Allergan, Alcon, Novartis, and Pfizer. He served as the Head of Retina Discovery and Vice President of Retina Translation Medicine at Allergan, where he was responsible for discovering and advancing new treatments for retinal diseases. His efforts at Allergan focused on identifying biomarkers and methods quantifying retina functional changes that predict disease progression. These efforts formed the basis for clinical interventional studies of novel treatments for exudative age related macular degeneration and geographic atrophy.
Terry Dagnon, Clinical Regulatory Advisor
Terry Dagnon, Masters of Science of Science Regulatory Affairs San Diego State University, is Senior Vice President of Operations at Dohmen Life Science Services. He brings a track record of 25 years in ophthalmology drug development and regulatory approvals. Terry began his career in the pharmaceutical industry as the Regulatory Affairs Manager for U.S. Oncology. (formerly known as Physician Reliance Network Inc.). He continued his regulatory affairs career at Johnson & Johnson Medical Inc. with global regulatory. He then served as the North America Head of Regulatory Affairs at Alcon prior to joining DLSS in March 2014.
Alan Weiner, CMC Advisor
Dr. Alan Weiner, PhD in biochemistry from Rutgers University, established DrugDel Consulting, LLC and is well known in ophthalmic formulation and drug delivery system research and development. He brings a track record of 35+ years in the pharmaceutical and medical device industry, having held senior managerial positions across multiple disciplines. Alan was a founding scientist at both The Liposome Company and Escalon Ophthalmics; the latter also serving as Vice President of R&D. Prior to his current consulting role he was Senior Director, Pharmaceutics at Alcon Laboratories and had responsibility for development of ophthalmic drug delivery, pharmaceutical and surgical therapeutic products.